From theoretical synergy to clinical supra-additive toxicity

J Clin Oncol. 2009 Mar 20;27(9):1359-61. doi: 10.1200/JCO.2008.20.8595. Epub 2009 Feb 17.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / adverse effects
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Bevacizumab
  • Carcinoma, Renal Cell / blood supply
  • Carcinoma, Renal Cell / drug therapy*
  • Drug Synergism
  • Humans
  • Hypertension / chemically induced
  • Indoles / administration & dosage
  • Indoles / adverse effects
  • Kidney Neoplasms / blood supply
  • Kidney Neoplasms / drug therapy*
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / metabolism
  • Pyrroles / administration & dosage
  • Pyrroles / adverse effects
  • Sunitinib
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Indoles
  • Pyrroles
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Sunitinib